肝细胞-话题@MedSci

#肝细胞#

513篇内容 | 2111人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1863658, encodeId=37e618636588a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：晚期肝细胞癌的更佳一线+二线序贯疗法, objectType=article, longId=299978, objectId=e2a32999e851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2a32999e851, replyNumber=0, likeNumber=88, createdTime=2022-08-06, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2a32999e851, moduleTitle=Liver Cancer：晚期肝细胞癌的更佳一线+二线序贯疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2a32999e851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863618, encodeId=d12418636185f, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, objectType=article, longId=219491, objectId=16ac219491e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ac219491e4, replyNumber=0, likeNumber=52, createdTime=2022-07-08, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ac219491e4, moduleTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16ac219491e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863648, encodeId=17b2186364808, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后, objectType=article, longId=295066, objectId=890729506606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=890729506606, replyNumber=0, likeNumber=58, createdTime=2022-10-07, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=890729506606, moduleTitle=Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=890729506606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863606, encodeId=c39b186360620, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：FOLFOX方案肝动脉灌注化疗(HAIC)联合索拉非尼较单用HAIC改善晚期肝细胞癌的预后, objectType=article, longId=217919, objectId=fd5021e9197a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5021e9197a, replyNumber=0, likeNumber=69, createdTime=2022-03-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5021e9197a, moduleTitle=Front Oncol：FOLFOX方案肝动脉灌注化疗(HAIC)联合索拉非尼较单用HAIC改善晚期肝细胞癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5021e9197a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863577, encodeId=d72a18635e7b6, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Hepatology：肝内胆管癌和肝细胞癌的临床特征和预后差异！, objectType=article, longId=212789, objectId=f7f1212e899d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7f1212e899d, replyNumber=0, likeNumber=136, createdTime=2022-04-21, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7f1212e899d, moduleTitle=Hepatology：肝内胆管癌和肝细胞癌的临床特征和预后差异！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7f1212e899d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863661, encodeId=78f018636613a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Clin Cancer Res：可预测晚期肝细胞癌对信迪利单抗联合IBI305治疗反应的生物标志物！, objectType=article, longId=300902, objectId=92d130090243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92d130090243, replyNumber=0, likeNumber=78, createdTime=2022-09-17, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92d130090243, moduleTitle=Clin Cancer Res：可预测晚期肝细胞癌对信迪利单抗联合IBI305治疗反应的生物标志物！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92d130090243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863578, encodeId=1edb18635e8c1, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Br J Cancer：中性粒细胞淋巴细胞比值NLR在肝细胞癌中的预后和诊断意义, objectType=article, longId=212793, objectId=f8b4212e9393, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8b4212e9393, replyNumber=0, likeNumber=87, createdTime=2022-05-07, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8b4212e9393, moduleTitle=Br J Cancer：中性粒细胞淋巴细胞比值NLR在肝细胞癌中的预后和诊断意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8b4212e9393)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863584, encodeId=74bd186358422, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, objectType=article, longId=213622, objectId=76842136220f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76842136220f, replyNumber=0, likeNumber=124, createdTime=2022-05-05, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76842136220f, moduleTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76842136220f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863579, encodeId=dd0618635e956, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Nat Commun：单细胞RNA测序揭示肝细胞癌的免疫抑制景观和肿瘤异质性, objectType=article, longId=213088, objectId=0d5a21308865, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d5a21308865, replyNumber=0, likeNumber=68, createdTime=2022-02-28, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d5a21308865, moduleTitle=Nat Commun：单细胞RNA测序揭示肝细胞癌的免疫抑制景观和肿瘤异质性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d5a21308865)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863607, encodeId=c2f4186360e43, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, objectType=article, longId=217963, objectId=568c21e96338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=568c21e96338, replyNumber=0, likeNumber=69, createdTime=2022-05-29, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=568c21e96338, moduleTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=568c21e96338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863593, encodeId=ce9c1863593d1, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究, objectType=article, longId=214768, objectId=1da3214e68e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da3214e68e5, replyNumber=0, likeNumber=85, createdTime=2022-04-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da3214e68e5, moduleTitle=J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da3214e68e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863608, encodeId=320f1863608c8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：肝细胞癌患者早期抗生素暴露反而更有可能从免疫治疗中获益, objectType=article, longId=218268, objectId=23ce21826849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23ce21826849, replyNumber=0, likeNumber=74, createdTime=2022-08-06, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23ce21826849, moduleTitle=Liver Cancer：肝细胞癌患者早期抗生素暴露反而更有可能从免疫治疗中获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23ce21826849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863634, encodeId=674f186363454, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=JGH：肿瘤负荷评分可以作为肝细胞癌患者接受经动脉化疗栓塞术的新预后标志物, objectType=article, longId=292063, objectId=557f29206341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=557f29206341, replyNumber=0, likeNumber=81, createdTime=2022-07-27, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=557f29206341, moduleTitle=JGH：肿瘤负荷评分可以作为肝细胞癌患者接受经动脉化疗栓塞术的新预后标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=557f29206341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863601, encodeId=13cc18636011b, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=JAM：低脂素食对成人超重体重、胰岛素敏感性、餐后代谢及心肌细胞和肝细胞脂质水平的影响, objectType=article, longId=217548, objectId=097021e548b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=097021e548b8, replyNumber=0, likeNumber=86, createdTime=2021-12-14, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=097021e548b8, moduleTitle=JAM：低脂素食对成人超重体重、胰岛素敏感性、餐后代谢及心肌细胞和肝细胞脂质水平的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=097021e548b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, objectType=article, longId=219191, objectId=02ce219191a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02ce219191a0, replyNumber=0, likeNumber=57, createdTime=2022-09-25, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ce219191a0, moduleTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02ce219191a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863594, encodeId=aec51863594a7, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Cell Death Dis：BH3-only蛋白表达水平决定肝细胞癌患者对基于索拉非尼的药物组合治疗的反应, objectType=article, longId=214946, objectId=404121494698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=404121494698, replyNumber=0, likeNumber=66, createdTime=2022-02-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=404121494698, moduleTitle=Cell Death Dis：BH3-only蛋白表达水平决定肝细胞癌患者对基于索拉非尼的药物组合治疗的反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=404121494698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863605, encodeId=0f6a186360552, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=J HEPATOLOGY：索拉非尼能改善HCV相关的肝细胞癌患者的肿瘤生长速度和肝功能, objectType=article, longId=217900, objectId=485421e90077, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=485421e90077, replyNumber=0, likeNumber=83, createdTime=2022-07-03, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=485421e90077, moduleTitle=J HEPATOLOGY：索拉非尼能改善HCV相关的肝细胞癌患者的肿瘤生长速度和肝功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=485421e90077)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863590, encodeId=8f851863590c8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=J Gastroenterology H：肌肉体积在乐伐替尼治疗肝细胞癌中的临床重要性, objectType=article, longId=214380, objectId=623c21438048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623c21438048, replyNumber=0, likeNumber=57, createdTime=2022-03-04, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623c21438048, moduleTitle=J Gastroenterology H：肌肉体积在乐伐替尼治疗肝细胞癌中的临床重要性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=623c21438048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863649, encodeId=61621863649a7, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=一出手即降低肝细胞癌术后1、3、5年复发风险近8成！这个“神药”是真全能！, objectType=article, longId=295106, objectId=02552951066a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02552951066a, replyNumber=0, likeNumber=83, createdTime=2022-04-10, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02552951066a, moduleTitle=一出手即降低肝细胞癌术后1、3、5年复发风险近8成！这个“神药”是真全能！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02552951066a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863602, encodeId=fd851863602dc, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期, objectType=article, longId=217593, objectId=2b2621e5937a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b2621e5937a, replyNumber=0, likeNumber=79, createdTime=2021-12-25, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b2621e5937a, moduleTitle=Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b2621e5937a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肝细胞

2020-05-29

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：晚期肝细胞癌的更佳一线+二线序贯疗法

2022-08-06

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效

2022-07-08

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后

2022-10-07

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：FOLFOX方案肝动脉灌注化疗(HAIC)联合索拉非尼较单用HAIC改善晚期肝细胞癌的预后

2022-03-11

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Hepatology：肝内胆管癌和肝细胞癌的临床特征和预后差异！

2022-04-21

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Clin Cancer Res：可预测晚期肝细胞癌对信迪利单抗联合IBI305治疗反应的生物标志物！

2022-09-17

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Br J Cancer：中性粒细胞淋巴细胞比值NLR在肝细胞癌中的预后和诊断意义

2022-05-07

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新

2022-05-05

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Nat Commun：单细胞RNA测序揭示肝细胞癌的免疫抑制景观和肿瘤异质性

2022-02-28

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效

2022-05-29

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究

2022-04-11

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：肝细胞癌患者早期抗生素暴露反而更有可能从免疫治疗中获益

2022-08-06

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

JGH：肿瘤负荷评分可以作为肝细胞癌患者接受经动脉化疗栓塞术的新预后标志物

2022-07-27

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

JAM：低脂素食对成人超重体重、胰岛素敏感性、餐后代谢及心肌细胞和肝细胞脂质水平的影响

2021-12-14

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性

2022-09-25

智智灵药 (审核中...)

前往app查看评论内容

#肝细胞#

Cell Death Dis：BH3-only蛋白表达水平决定肝细胞癌患者对基于索拉非尼的药物组合治疗的反应

2022-02-27

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

J HEPATOLOGY：索拉非尼能改善HCV相关的肝细胞癌患者的肿瘤生长速度和肝功能

2022-07-03

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

J Gastroenterology H：肌肉体积在乐伐替尼治疗肝细胞癌中的临床重要性

2022-03-04

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

一出手即降低肝细胞癌术后1、3、5年复发风险近8成！这个“神药”是真全能！

2022-04-10

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期

2021-12-25

科室
- - 订阅+
  - 更多科室
工具
服务